NEW YORK (GenomeWeb News) – PerkinElmer reported after the close of the market Thursday that its fourth-quarter revenues rose 6 percent, while its bottom line was hit by a large asset impairments charge.

The Waltham, Mass.-based analytical tools firm brought in total revenues of $572.9 million for the three months ended Dec. 30, 2012, compared to $539.3 million for the fourth quarter of 2011, and up 3 percent on an organic basis. It beat Wall Street's estimate of $578.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.